EXACT Sciences Corporation (NASDAQ: EXAS), a research and development company focused on developing non-invasive screening technologies for early detection of colorectal cancer, recently announced published results of a comprehensive colorectal cancer detection study in which stool and blood plasma were individually assessed to determine which type of testing was more accurate in detecting the dis